All companies › MIRM

MIRM · Mirum Pharmaceuticals, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells5
Research cases0
Last filing2026-09-14

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-08-18 — Howe Jolanda · sold 40,000 @ $100.00 2026-09-01 — Peetz Christopher · sold 21,688 @ $98.91 2026-09-01 — Peetz Christopher · sold 8,312 @ $98.08 2026-09-02 — Howe Jolanda · sold 658 @ $100.00 2026-09-14 — BJERKHOLT ERIC · sold 9,943 @ $98.37
2026-08-182026-09-14

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Howe Jolanda SVP, GLOBAL CONTROLLER
Peetz Christopher CHIEF EXECUTIVE OFFICER, Director
BJERKHOLT ERIC CHIEF FINANCIAL OFFICER
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $MIRM is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-14', 'insider_name': 'BJERKHOLT ERIC', 'insider_title': 'CHIEF FINANCIAL OFFICER', 'transaction_type': 'Open-market sell', 'shares': 9943.0, 'price': 98.37, 'value': 978092.91, 'is_buy': False}, {'transaction_date': '2026-09-02', 'insider_name': 'Howe Jolanda', 'insider_title': 'SVP, GLOBAL CONTROLLER', 'transaction_type': 'Open-market sell', 'shares': 658.0, 'price': 100.0, 'value': 65800.0, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Peetz Christopher', 'insider_title': 'CHIEF EXECUTIVE OFFICER, Director', 'transaction_type': 'Open-market sell', 'shares': 21688.0, 'price': 98.91, 'value': 2145160.08, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Peetz Christopher', 'insider_title': 'CHIEF EXECUTIVE OFFICER, Director', 'transaction_type': 'Open-market sell', 'shares': 8312.0, 'price': 98.08, 'value': 815240.96, 'is_buy': False}, {'transaction_date': '2026-08-18', 'insider_name': 'Howe Jolanda', 'insider_title': 'SVP, GLOBAL CONTROLLER', 'transaction_type': 'Open-market sell', 'shares': 40000.0, 'price': 100.0, 'value': 4000000.0, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for MIRM today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.